Phase I and II Studies


Click here to start

Table of Contents

Phase I and II Studies

Patient Exposure

RAPAMUNE Phase I Trials

RAPAMUNE Phase II Trials Renal Transplant Recipients

Phase II Multicenter Trial: RAPAMUNE with Full- vs Reduced-Dose SandimmuneŽ*

Incidence of Biopsy-Confirmed Acute Rejection (6 Months)

RAPAMUNE Combined With Standard- or Reduced-Dose Cyclosporine: Differences By Race

Phase II Safety Profile of RAPAMUNE Supported Phase III Combination Studies

Rationale for Phase III Trials Dose Selection

Author: James Sergi